Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection

European Journal of Haematology

Volumn 72, Issue 1, 2004, Pages 64-66

  Heider, Ulrike ^a   Fleissner, Claudia ^a   Zavrski, Ivana ^a   Jakob, Christian ^a   Dietzel, Toralf ^a   Eucker, Jan ^a   Ockenga, Johann ^a   Possinger, Kurt ^a   Sezer, Orhan ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Campath 1H; Chronic hepatitis B; CLL

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; LAMIVUDINE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; VINCRISTINE;

AGED; ANEMIA; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CASE REPORT; CHRONIC HEPATITIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; FEVER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; NAUSEA; PRIORITY JOURNAL; RASH; RIGOR; SERODIAGNOSIS; SYMPTOM; THROMBOCYTOPENIA; VIROGENESIS; VIRUS LOAD;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0742269485     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0902-4441.2004.00180.x     Document Type: Article

References (22)

1. HALE G, XIA MQ, TIGHE HP, DYER MJ, WALDMANN H. The CAMPATH-1 antigen (CD52). Tissue Antigens 1990;35:118-127.
2. LUNDIN J, OSTERBORG A. BRITTINGER G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H treatment in low-erade non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3257-3263.
3. OSTERBORG A, DYER MJ, BUNJES D, PANGALIS GA, BASTION Y, CATOVSKY D, MELLSTEDT H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997;15:1567-1574.
4. KNOX SJ, GORIS ML, TRISLER K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457-470.
5. ROSSI G, PELIZZARI A, MOTTA M, PUOTI M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58-62.
6. HALE G, WALDMANN H, DYER M. Specificity of monoclonal antibody Campath-1. Bone Marrow Transplant 1988; 3:237-239.
7. OSTERBORG A, MELLSTEDT H, KEATING M. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Med Oncol 2002;19 (Suppl.):S21-6.
8. CONDIOTTI R, NAGLER A. Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity. Bone Marrow Transplant 1996;18:713-720.
9. CHAKRAVERTY R, ROBINSON S, PEGGS K, et al. Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplant 2001;28:827-834.
10. LUNDIN J, KIMBY E, BJORKHOLM M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-773.
11. BOWEN AL, ZOMAS A, EMMETT E, MATUTES E, DYER MJ, CATOVSKY D. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 1997;96:617-619.
12. CAVALLI-BJORKMAN N, OSBY E, LUNDIN J, KALIN M, OSTERBORG A, GRUBER A. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia. Med Oncol 2002;19:277-280.
13. CROWLEY B, WOODCOCK B. Red cell aplasia due to parvo-virus b19 in a patient treated with alemtuzumab. Br J Haematol 2002;119:279-280.
14. YEO W, CHAN PK, ZHONG S, HO WM, STEINBERG JL, TAM JS, HUI P, LEUNG NW, ZEE B, JOHNSON PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
15. DERVITE I, HOBER D, MOREL P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-69.
16. LIAW YF, CHU CM, SU IJ, HUANG MJ, LIN DY, CHANG-CHIEN CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983;84:216-219.
17. LOK AS, MCMAHON BJ, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001;34:1225-1241.
18. YEO W, STEINBERG JL, TAM JS, CHAN PK, LEUNG NW, LAM KC, MOK TS, JOHNSON PJ. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999;59:263-269.
19. SILVESTRI F, ERMACORA A, SPEROTTO A, PATRIARCA F, ZAJA F, DAMIANI D, FANIN R, BACCARANI M. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 2000;108:394-396.
20. MAGUIRE CM, CRAWFORD DH, HOURIGAN LF, CLOUSTON AD, WALPOLE ET, POWELL EE. Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy. J Gastroenterol Hepatol 1999;14:801-803.
21. CLARK FL, DRUMMOND MW, CHAMBERS S, CHAPMAN BA, PATTON WN. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol 1998;9:385-387.
22. HAMAKI T, KAMI M, KUSUMI E, UEYAMA J, MIYAKOSHI S, MORINAGA S, MUTOU Y. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001;68:292-294.